Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Indirect-Acting Cholinergic Agonists: Pharmacological Actions01:30

Indirect-Acting Cholinergic Agonists: Pharmacological Actions

1.8K
Indirect-acting cholinergic agonists, also known as anticholinesterases, exert their pharmacological effects by enhancing cholinergic transmission in various body parts, including the neuromuscular junction, autonomic cholinergic synapses, and the brain.
At the neuromuscular junction, these agents work by inhibiting the breakdown of acetylcholine, allowing it to remain bound to the receptor and bind to nearby receptors. This process leads to repetitive firing of the endplate, causing muscle...
1.8K
Myasthenia Gravis: Overview and Treatment01:20

Myasthenia Gravis: Overview and Treatment

3.7K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
3.7K
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

1.3K
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
1.3K
Antiepileptic Drugs: Glutamate Antagonists01:14

Antiepileptic Drugs: Glutamate Antagonists

1.3K
Glutamate is a fundamental neurotransmitter in the central nervous system, playing a vital role in neuronal communication and various cognitive processes. Glutamate stands as the principal excitatory neurotransmitter in the brain. Its presence is crucial for the communication between neurons, underpinning essential processes such as synaptic transmission, neuronal excitability, and plasticity. These functions are vital for higher-order cognitive processes, including learning and memory. The...
1.3K
Encephalitis ll: Pathophysiology01:26

Encephalitis ll: Pathophysiology

22
Encephalitis is inflammation of the brain parenchyma caused by direct viral invasion or immune-mediated mechanisms triggered by infections or tumors. Both processes lead to neuronal injury, disrupted neurotransmission, and diverse neurological symptoms, often with overlapping clinical and pathological features.Autoimmune EncephalitisIn autoimmune encephalitis, antibodies target neuronal antigens on cell surfaces, synapses, or within neurons. A key example is anti-NMDAR encephalitis, which can...
22
Myasthenia Gravis ll: Pathophysiology01:22

Myasthenia Gravis ll: Pathophysiology

53
The disease process of myasthenia gravis begins at the neuromuscular junction, where antibodies attack key proteins needed for muscle activation. This immune reaction weakens signal transmission, leading to the characteristic muscle fatigue and weakness that define the condition.Immune-Mediated DamageIn most individuals, antibodies target acetylcholine receptors (AChRs) on the postsynaptic membrane of muscle cells. By blocking acetylcholine binding, these antibodies prevent the nerve signal...
53

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[The clinical efficacy of unilateral biportal endoscopy contralateral inclinatory approach in the treatment of lumbar foraminal stenosis].

Zhonghua wai ke za zhi [Chinese journal of surgery]·2026
Same author

[Nasal infection with Mycobacterium avium complex: a case report].

Zhonghua er bi yan hou tou jing wai ke za zhi = Chinese journal of otorhinolaryngology head and neck surgery·2025
Same author

Effect of stump-preserving arthroscopic reconstruction or stump-eliminating arthroscopic reconstruction combined with exercise rehabilitation therapy on knee functional recovery in patients with anterior cruciate ligament injuries.

Annals of the Royal College of Surgeons of England·2025
Same author

[A case of thoracic aortic aneurysm after coronary artery bypass grafting was treated with integrative branch stent combined with extracorporeal fenestration technique and internal branch technique].

Zhonghua xin xue guan bing za zhi·2025
Same author

Quantum Electrodynamics in Strong Electromagnetic Fields: Substate Resolved Kα Transition Energies in Heliumlike Uranium.

Physical review letters·2025
Same author

Association of treatment methods and survival in esophageal neuroendocrine carcinoma population of Surveillance, Epidemiology, and End Results database: a retrospective cohort study.

Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus·2025

Related Experiment Video

Updated: May 1, 2026

Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination
09:38

Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination

Published on: September 12, 2016

16.0K

Autoimmune encephalomyelitis ameliorated by AMPA antagonists.

T Smith1, A Groom, B Zhu

  • 1Eisai London Research Laboratories, Bernard Katz Building, University College London, Gower Street, London WC1E 6BT, UK.

Nature Medicine
|December 29, 1999
PubMed
Summary

This study reveals that neurons, not just myelin, are attacked in experimental autoimmune encephalomyelitis, a model for multiple sclerosis. Blocking glutamate AMPA receptors improved neurological symptoms, suggesting a new therapeutic target.

More Related Videos

Induction and Diverse Assessment Indicators of Experimental Autoimmune Encephalomyelitis
06:19

Induction and Diverse Assessment Indicators of Experimental Autoimmune Encephalomyelitis

Published on: September 9, 2022

4.0K
Author Spotlight: Novel Assay for Studying B-Cell Responses in Multiple Sclerosis Research
05:55

Author Spotlight: Novel Assay for Studying B-Cell Responses in Multiple Sclerosis Research

Published on: December 1, 2023

1.4K

Related Experiment Videos

Last Updated: May 1, 2026

Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination
09:38

Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination

Published on: September 12, 2016

16.0K
Induction and Diverse Assessment Indicators of Experimental Autoimmune Encephalomyelitis
06:19

Induction and Diverse Assessment Indicators of Experimental Autoimmune Encephalomyelitis

Published on: September 9, 2022

4.0K
Author Spotlight: Novel Assay for Studying B-Cell Responses in Multiple Sclerosis Research
05:55

Author Spotlight: Novel Assay for Studying B-Cell Responses in Multiple Sclerosis Research

Published on: December 1, 2023

1.4K

Area of Science:

  • Neuroimmunology
  • Neurology
  • Pathology

Background:

  • Multiple sclerosis (MS) is an immune-mediated central nervous system disorder causing progressive motor and sensory decline.
  • Current therapies for MS offer only partial effectiveness.
  • While myelin loss is a hallmark, its extent doesn't always correlate with neurological severity in MS models.

Purpose of the Study:

  • To investigate potential targets beyond myelin in the pathogenesis of experimental autoimmune encephalomyelitis (EAE), an MS model.
  • To explore the role of neuronal damage in EAE.
  • To assess the therapeutic potential of glutamate AMPA receptor antagonists in EAE.

Main Methods:

  • Induction of experimental autoimmune encephalomyelitis (EAE) in animal models.
  • Histopathological examination of spinal cord tissue to identify sites of immune attack.
  • Administration of glutamate AMPA receptor antagonists to EAE subjects.
  • Assessment of neurological sequelae following treatment.

Main Results:

  • Lymphocyte-mediated attack and neuronal degeneration were observed in the spinal cord during EAE.
  • Demyelination extent did not consistently correlate with neurological decline severity.
  • Blockade of glutamate AMPA receptors significantly ameliorated neurological symptoms in EAE.

Conclusions:

  • Neuronal damage is a significant pathological feature in EAE, independent of myelin destruction.
  • Glutamate AMPA receptors represent a potential therapeutic target for MS.
  • AMPA antagonists may offer a novel treatment strategy for multiple sclerosis.